DelveInsight’s “Alpha-1 Antitrypsin Deficiency Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Alpha-1 Antitrypsin Deficiency, historical and forecasted epidemiology as well as the Alpha-1 Antitrypsin Deficiency market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Alpha-1 Antitrypsin Deficiency market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Alpha-1 Antitrypsin Deficiency Market Forecast
Some of the key facts of the Alpha-1 Antitrypsin Deficiency Market Report:
-
Among the 7MM countries, Alpha-1 Antitrypsin Deficiency market size was valued approximately USD 1,169 million in 2022 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
-
Among the 7MM, the US held the largest market share for alpha-1 antitrypsin deficiency, generating nearly USD 931.32 million in revenue in 2022, followed by Germany, France, the UK, and other countries.
-
In 2022, the total market size for alpha-1 antitrypsin deficiency in the EU4 and the UK was nearly USD 237.78 million, accounting for approximately 20.33% of the total market revenue in the 7MM.
-
According to DelveInsight's analysis, in 2022, the US had the highest prevalence of alpha-1 antitrypsin deficiency (AATD) among the 7MM, accounting for approximately 60.14% of cases. The UK followed with nearly 10.26%, and Germany with about 9.08%.
-
In 2022, the US had approximately 119,274 cases of the PiZZ genotype, 7,316 cases of the PiSZ genotype, and 5,937 cases of other genotypes.
-
In the EU4 and the UK, of the total prevalent cases of AATD in 2022, approximately 77.76% were PiZZ genotypes, 10.39% were PiSZ genotypes, and nearly 11.85% were other genotypes.
-
In March 2024, Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company specializing in precision genetic medicines through base editing, announced that the United Kingdom Medicines and Healthcare Products Regulatory Agency has cleared its clinical trial authorization (CTA) application for BEAM-302, an in vivo base editor intended as a potential treatment for patients with alpha-1 antitrypsin deficiency (AATD).
-
In September 2023, The US Food and Drug Administration has approved Krystal Biotech’s Investigational New Drug (IND) application for a Phase I clinical trial of KB408, an investigational treatment for alpha-1 antitrypsin deficiency (AATD).
-
In July 2023, Grifols has achieved the target enrollment of 339 subjects in the Phase III SPARTA (Study of Prolastin-C Randomized Therapy with Alpha-1 Augmentation) trial for treating emphysema. This placebo-controlled, double-blind, randomized study aims to evaluate the safety and efficacy of 60mg/kg and 120mg/kg doses of Alpha1-Proteinase inhibitor Prolastin-C, administered weekly, in slowing the progression of lung tissue loss in emphysema patients.
-
In May 2023, Inhibrx, Inc. (Nasdaq: INBX), a clinical-stage biopharmaceutical company focused on developing therapies for oncology and rare diseases, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to INBRX-101, an optimized recombinant human AAT-Fc fusion protein, for treating patients with emphysema due to alpha-1 antitrypsin deficiency (AATD).
-
Key Alpha-1 Antitrypsin Deficiency Companies: Kamada Pharmaceuticals, Mereo BioPharma/AstraZeneca, Grifols Therapeutics LLC, Takeda, Vertex Pharmaceuticals, Wave Life Sciences, Beam Therapeutics, Arrowhead Pharmaceuticals, Inhibrx, Inc., Dicerna Pharmaceuticals, Grifols Therapeutics LLC, and others
-
Key Alpha-1 Antitrypsin Deficiency Therapies: Inhaled Alpha 1-Antitrypsin (AAT), Alvelestat (MPH966), Alpha-1 15%, VX-864, WVE-006, BEAM-302, Fazirsiran Injection (TAK-999, ARO-AAT), INBRX-101, Belcesiran, Alpha-1 MP, and others
-
The Alpha-1 Antitrypsin Deficiency market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Alpha-1 Antitrypsin Deficiency pipeline products will significantly revolutionize the Alpha-1 Antitrypsin Deficiency market dynamics.
Alpha-1 Antitrypsin Deficiency Overview
Alpha-1 Antitrypsin Deficiency (AATD) is a genetic disorder that affects the liver and lungs. It occurs when there is a deficiency in the production of alpha-1 antitrypsin (AAT) protein, which is mainly produced by the liver and helps protect the lungs from damage caused by inflammation. Without enough AAT, the walls of the lungs can be damaged by enzymes released from white blood cells, leading to conditions such as emphysema and chronic obstructive pulmonary disease (COPD).
Get a Free sample for the Alpha-1 Antitrypsin Deficiency Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/alpha-1-antitrypsin-deficiency-a1atd-market
Alpha-1 Antitrypsin Deficiency Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Alpha-1 Antitrypsin Deficiency Epidemiology Segmentation:
The Alpha-1 Antitrypsin Deficiency market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
-
Total Prevalence of Alpha-1 Antitrypsin Deficiency
-
Prevalent Cases of Alpha-1 Antitrypsin Deficiency by severity
-
Gender-specific Prevalence of Alpha-1 Antitrypsin Deficiency
-
Diagnosed Cases of Episodic and Chronic Alpha-1 Antitrypsin Deficiency
Download the report to understand which factors are driving Alpha-1 Antitrypsin Deficiency epidemiology trends @ Alpha-1 Antitrypsin Deficiency Epidemiology Forecast
Alpha-1 Antitrypsin Deficiency Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Alpha-1 Antitrypsin Deficiency market or expected to get launched during the study period. The analysis covers Alpha-1 Antitrypsin Deficiency market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Alpha-1 Antitrypsin Deficiency Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Alpha-1 Antitrypsin Deficiency Therapies and Key Companies
-
Alpha-1 15%: Grifols Therapeutics LLC
-
Fazirsiran Injection: Takeda
-
VX-864: Vertex Pharmaceuticals
-
WVE-006: Wave Life Sciences
-
BEAM-302: Beam Therapeutics
-
Fazirsiran Injection (TAK-999, ARO-AAT): Arrowhead Pharmaceuticals
-
INBRX-101: Inhibrx, Inc.
-
Belcesiran: Dicerna Pharmaceuticals
-
Alpha-1 MP: Grifols Therapeutics LLC
Discover more about therapies set to grab major Alpha-1 Antitrypsin Deficiency market share @ Alpha-1 Antitrypsin Deficiency Treatment Landscape
Alpha-1 Antitrypsin Deficiency Market Strengths
-
Ongoing research and an increase in disease understanding have led to the identification of therapies with effective and convenient routes of administration, including subcutaneous, inhalation, and oral, with the potential to improve patient’s QoL.
-
Active patient registries and support organizations provide information, advocacy, and support to alpha-1 antitrypsin deficiency individuals
Alpha-1 Antitrypsin Deficiency Market Opportunities
-
Several preclinical and early-phase assets utilizing novel approaches like RNA editing and gene therapy are under investigation, and conducting further research and clinical trials may offer curative therapy.
-
No therapies are approved for liver disease associated with alpha-1 antitrypsin deficiency, allowing pharma players to capitalize on this untapped market by grabbing first mover advantage.
Scope of the Alpha-1 Antitrypsin Deficiency Market Report
-
Study Period: 2019–2032
-
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
-
Key Alpha-1 Antitrypsin Deficiency Companies: Kamada Pharmaceuticals, Mereo BioPharma/AstraZeneca, Grifols Therapeutics LLC, Takeda, Vertex Pharmaceuticals, Wave Life Sciences, Beam Therapeutics, Arrowhead Pharmaceuticals, Inhibrx, Inc., Dicerna Pharmaceuticals, Grifols Therapeutics LLC, and others
-
Key Alpha-1 Antitrypsin Deficiency Therapies: Inhaled Alpha 1-Antitrypsin (AAT), Alvelestat (MPH966), Alpha-1 15%, VX-864, WVE-006, BEAM-302, Fazirsiran Injection (TAK-999, ARO-AAT), INBRX-101, Belcesiran, Alpha-1 MP, and others
-
Alpha-1 Antitrypsin Deficiency Therapeutic Assessment: Alpha-1 Antitrypsin Deficiency current marketed and Alpha-1 Antitrypsin Deficiency emerging therapies
-
Alpha-1 Antitrypsin Deficiency Market Dynamics: Alpha-1 Antitrypsin Deficiency market drivers and Alpha-1 Antitrypsin Deficiency market barriers
-
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
-
Alpha-1 Antitrypsin Deficiency Unmet Needs, KOL’s views, Analyst’s views, Alpha-1 Antitrypsin Deficiency Market Access and Reimbursement
To know more about Alpha-1 Antitrypsin Deficiency companies working in the treatment market, visit @ Alpha-1 Antitrypsin Deficiency Clinical Trials and Therapeutic Assessment
Table of Contents
1. Alpha-1 Antitrypsin Deficiency Market Report Introduction
2. Executive Summary for Alpha-1 Antitrypsin Deficiency
3. SWOT analysis of Alpha-1 Antitrypsin Deficiency
4. Alpha-1 Antitrypsin Deficiency Patient Share (%) Overview at a Glance
5. Alpha-1 Antitrypsin Deficiency Market Overview at a Glance
6. Alpha-1 Antitrypsin Deficiency Disease Background and Overview
7. Alpha-1 Antitrypsin Deficiency Epidemiology and Patient Population
8. Country-Specific Patient Population of Alpha-1 Antitrypsin Deficiency
9. Alpha-1 Antitrypsin Deficiency Current Treatment and Medical Practices
10. Alpha-1 Antitrypsin Deficiency Unmet Needs
11. Alpha-1 Antitrypsin Deficiency Emerging Therapies
12. Alpha-1 Antitrypsin Deficiency Market Outlook
13. Country-Wise Alpha-1 Antitrypsin Deficiency Market Analysis (2019–2032)
14. Alpha-1 Antitrypsin Deficiency Market Access and Reimbursement of Therapies
15. Alpha-1 Antitrypsin Deficiency Market Drivers
16. Alpha-1 Antitrypsin Deficiency Market Barriers
17. Alpha-1 Antitrypsin Deficiency Appendix
18. Alpha-1 Antitrypsin Deficiency Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
